The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human Growth Hormone Deficiency (Ghd) Drug-Global Market Insights and Sales Trends 2024
Synopsis
The global Human Growth Hormone Deficiency (Ghd) Drug market size is expected to reach US$ 5187.8 million by 2029, growing at a CAGR of 4.0% from 2023 to 2029. The market is mainly driven by the significant applications of Human Growth Hormone Deficiency (Ghd) Drug in various end use industries. The expanding demands from the Children and Adults, are propelling Human Growth Hormone Deficiency (Ghd) Drug market. TransCon-hGH, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Somapacitan segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Growth Hormone Deficiency (Ghd) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Growth Hormone Deficiency (Ghd) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Growth Hormone Deficiency (Ghd) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Growth Hormone Deficiency (Ghd) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Growth Hormone Deficiency (Ghd) Drug covered in this report include AnkeBio Co. Ltd, Eli Lilly and Company, EMD Serono Inc., Ferring Pharmaceuticals, Genentech, Inc (Roche), GeneScience Pharmaceuticals Co. Ltd, Ipsen S.A., LG Life Sciences and Merck KGaA, etc.
The global Human Growth Hormone Deficiency (Ghd) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AnkeBio Co. Ltd
Eli Lilly and Company
EMD Serono Inc.
Ferring Pharmaceuticals
Genentech, Inc (Roche)
GeneScience Pharmaceuticals Co. Ltd
Ipsen S.A.
LG Life Sciences
Merck KGaA
Sandoz International GmbH (Novartis AG)
Strongbridge Biopharma
Teva Pharmaceutical Industries, Ltd
Novo Nordisk A/S
Pfizer Inc
Opko Health, Inc.
Ascendis Pharma A/S
Versartis Inc.
Global Human Growth Hormone Deficiency (Ghd) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Growth Hormone Deficiency (Ghd) Drug market, Segment by Type:
TransCon-hGH
Somapacitan
Somavaratan
Others
Global Human Growth Hormone Deficiency (Ghd) Drug market, by Application
Children
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Growth Hormone Deficiency (Ghd) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Growth Hormone Deficiency (Ghd) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Human Growth Hormone Deficiency (Ghd) Drug market size is expected to reach US$ 5187.8 million by 2029, growing at a CAGR of 4.0% from 2023 to 2029. The market is mainly driven by the significant applications of Human Growth Hormone Deficiency (Ghd) Drug in various end use industries. The expanding demands from the Children and Adults, are propelling Human Growth Hormone Deficiency (Ghd) Drug market. TransCon-hGH, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Somapacitan segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Growth Hormone Deficiency (Ghd) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Growth Hormone Deficiency (Ghd) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Growth Hormone Deficiency (Ghd) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Growth Hormone Deficiency (Ghd) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Growth Hormone Deficiency (Ghd) Drug covered in this report include AnkeBio Co. Ltd, Eli Lilly and Company, EMD Serono Inc., Ferring Pharmaceuticals, Genentech, Inc (Roche), GeneScience Pharmaceuticals Co. Ltd, Ipsen S.A., LG Life Sciences and Merck KGaA, etc.
The global Human Growth Hormone Deficiency (Ghd) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AnkeBio Co. Ltd
Eli Lilly and Company
EMD Serono Inc.
Ferring Pharmaceuticals
Genentech, Inc (Roche)
GeneScience Pharmaceuticals Co. Ltd
Ipsen S.A.
LG Life Sciences
Merck KGaA
Sandoz International GmbH (Novartis AG)
Strongbridge Biopharma
Teva Pharmaceutical Industries, Ltd
Novo Nordisk A/S
Pfizer Inc
Opko Health, Inc.
Ascendis Pharma A/S
Versartis Inc.
Global Human Growth Hormone Deficiency (Ghd) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Growth Hormone Deficiency (Ghd) Drug market, Segment by Type:
TransCon-hGH
Somapacitan
Somavaratan
Others
Global Human Growth Hormone Deficiency (Ghd) Drug market, by Application
Children
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Growth Hormone Deficiency (Ghd) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Growth Hormone Deficiency (Ghd) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Human Growth Hormone Deficiency (Ghd) Drug Market Overview
1.1 Human Growth Hormone Deficiency (Ghd) Drug Product Overview
1.2 Human Growth Hormone Deficiency (Ghd) Drug Market Segment by Type
1.2.1 TransCon-hGH
1.2.2 Somapacitan
1.2.3 Somavaratan
1.2.4 Others
1.3 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size by Type
1.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Type (2018-2023)
2 Global Human Growth Hormone Deficiency (Ghd) Drug Market Competition by Company
2.1 Global Top Players by Human Growth Hormone Deficiency (Ghd) Drug Sales (2018-2023)
2.2 Global Top Players by Human Growth Hormone Deficiency (Ghd) Drug Revenue (2018-2023)
2.3 Global Top Players by Human Growth Hormone Deficiency (Ghd) Drug Price (2018-2023)
2.4 Global Top Manufacturers Human Growth Hormone Deficiency (Ghd) Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Human Growth Hormone Deficiency (Ghd) Drug Market Competitive Situation and Trends
2.5.1 Human Growth Hormone Deficiency (Ghd) Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Human Growth Hormone Deficiency (Ghd) Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Growth Hormone Deficiency (Ghd) Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Human Growth Hormone Deficiency (Ghd) Drug Market
2.8 Key Manufacturers Human Growth Hormone Deficiency (Ghd) Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Human Growth Hormone Deficiency (Ghd) Drug Status and Outlook by Region
3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size by Region
3.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Region (2018-2023)
3.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Region
3.3.1 Global Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Region (2024-2029)
3.3.3 Global Human Growth Hormone Deficiency (Ghd) Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Human Growth Hormone Deficiency (Ghd) Drug by Application
4.1 Human Growth Hormone Deficiency (Ghd) Drug Market Segment by Application
4.1.1 Children
4.1.2 Adults
4.2 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size by Application
4.2.1 Global Human Growth Hormone Deficiency (Ghd) Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales Breakdown by Application (2018-2023)
5 North America Human Growth Hormone Deficiency (Ghd) Drug by Country
5.1 North America Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size by Country
5.1.1 North America Human Growth Hormone Deficiency (Ghd) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2018-2023)
5.2 North America Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Country
5.2.1 North America Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2024-2029)
6 Europe Human Growth Hormone Deficiency (Ghd) Drug by Country
6.1 Europe Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size by Country
6.1.1 Europe Human Growth Hormone Deficiency (Ghd) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2018-2023)
6.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Country
6.2.1 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug by Region
7.1 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size by Region
7.1.1 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Region (2024-2029)
8 Latin America Human Growth Hormone Deficiency (Ghd) Drug by Country
8.1 Latin America Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size by Country
8.1.1 Latin America Human Growth Hormone Deficiency (Ghd) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2018-2023)
8.2 Latin America Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Country
8.2.1 Latin America Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug by Country
9.1 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Historic Market Size by Country
9.1.1 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Human Growth Hormone Deficiency (Ghd) Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AnkeBio Co. Ltd
10.1.1 AnkeBio Co. Ltd Company Information
10.1.2 AnkeBio Co. Ltd Introduction and Business Overview
10.1.3 AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AnkeBio Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.1.5 AnkeBio Co. Ltd Recent Development
10.2 Eli Lilly and Company
10.2.1 Eli Lilly and Company Company Information
10.2.2 Eli Lilly and Company Introduction and Business Overview
10.2.3 Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eli Lilly and Company Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.2.5 Eli Lilly and Company Recent Development
10.3 EMD Serono Inc.
10.3.1 EMD Serono Inc. Company Information
10.3.2 EMD Serono Inc. Introduction and Business Overview
10.3.3 EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 EMD Serono Inc. Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.3.5 EMD Serono Inc. Recent Development
10.4 Ferring Pharmaceuticals
10.4.1 Ferring Pharmaceuticals Company Information
10.4.2 Ferring Pharmaceuticals Introduction and Business Overview
10.4.3 Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Ferring Pharmaceuticals Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.4.5 Ferring Pharmaceuticals Recent Development
10.5 Genentech, Inc (Roche)
10.5.1 Genentech, Inc (Roche) Company Information
10.5.2 Genentech, Inc (Roche) Introduction and Business Overview
10.5.3 Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Genentech, Inc (Roche) Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.5.5 Genentech, Inc (Roche) Recent Development
10.6 GeneScience Pharmaceuticals Co. Ltd
10.6.1 GeneScience Pharmaceuticals Co. Ltd Company Information
10.6.2 GeneScience Pharmaceuticals Co. Ltd Introduction and Business Overview
10.6.3 GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 GeneScience Pharmaceuticals Co. Ltd Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.6.5 GeneScience Pharmaceuticals Co. Ltd Recent Development
10.7 Ipsen S.A.
10.7.1 Ipsen S.A. Company Information
10.7.2 Ipsen S.A. Introduction and Business Overview
10.7.3 Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Ipsen S.A. Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.7.5 Ipsen S.A. Recent Development
10.8 LG Life Sciences
10.8.1 LG Life Sciences Company Information
10.8.2 LG Life Sciences Introduction and Business Overview
10.8.3 LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 LG Life Sciences Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.8.5 LG Life Sciences Recent Development
10.9 Merck KGaA
10.9.1 Merck KGaA Company Information
10.9.2 Merck KGaA Introduction and Business Overview
10.9.3 Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Merck KGaA Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.9.5 Merck KGaA Recent Development
10.10 Sandoz International GmbH (Novartis AG)
10.10.1 Sandoz International GmbH (Novartis AG) Company Information
10.10.2 Sandoz International GmbH (Novartis AG) Introduction and Business Overview
10.10.3 Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Sandoz International GmbH (Novartis AG) Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.10.5 Sandoz International GmbH (Novartis AG) Recent Development
10.11 Strongbridge Biopharma
10.11.1 Strongbridge Biopharma Company Information
10.11.2 Strongbridge Biopharma Introduction and Business Overview
10.11.3 Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Strongbridge Biopharma Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.11.5 Strongbridge Biopharma Recent Development
10.12 Teva Pharmaceutical Industries, Ltd
10.12.1 Teva Pharmaceutical Industries, Ltd Company Information
10.12.2 Teva Pharmaceutical Industries, Ltd Introduction and Business Overview
10.12.3 Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Teva Pharmaceutical Industries, Ltd Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.12.5 Teva Pharmaceutical Industries, Ltd Recent Development
10.13 Novo Nordisk A/S
10.13.1 Novo Nordisk A/S Company Information
10.13.2 Novo Nordisk A/S Introduction and Business Overview
10.13.3 Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Novo Nordisk A/S Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.13.5 Novo Nordisk A/S Recent Development
10.14 Pfizer Inc
10.14.1 Pfizer Inc Company Information
10.14.2 Pfizer Inc Introduction and Business Overview
10.14.3 Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Pfizer Inc Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.14.5 Pfizer Inc Recent Development
10.15 Opko Health, Inc.
10.15.1 Opko Health, Inc. Company Information
10.15.2 Opko Health, Inc. Introduction and Business Overview
10.15.3 Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Opko Health, Inc. Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.15.5 Opko Health, Inc. Recent Development
10.16 Ascendis Pharma A/S
10.16.1 Ascendis Pharma A/S Company Information
10.16.2 Ascendis Pharma A/S Introduction and Business Overview
10.16.3 Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Ascendis Pharma A/S Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.16.5 Ascendis Pharma A/S Recent Development
10.17 Versartis Inc.
10.17.1 Versartis Inc. Company Information
10.17.2 Versartis Inc. Introduction and Business Overview
10.17.3 Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Versartis Inc. Human Growth Hormone Deficiency (Ghd) Drug Products Offered
10.17.5 Versartis Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Human Growth Hormone Deficiency (Ghd) Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Human Growth Hormone Deficiency (Ghd) Drug Industrial Chain Analysis
11.4 Human Growth Hormone Deficiency (Ghd) Drug Market Dynamics
11.4.1 Human Growth Hormone Deficiency (Ghd) Drug Industry Trends
11.4.2 Human Growth Hormone Deficiency (Ghd) Drug Market Drivers
11.4.3 Human Growth Hormone Deficiency (Ghd) Drug Market Challenges
11.4.4 Human Growth Hormone Deficiency (Ghd) Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Human Growth Hormone Deficiency (Ghd) Drug Distributors
12.3 Human Growth Hormone Deficiency (Ghd) Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
